title: Long-term reduction of amplified ornithine decarboxylase sequences in human myeloma cells.
abstract: (1) Human myeloma cell line Sultan, resistant to 20 mM difluoro-methylornithine (DFMO) owing to ornithine decarboxylase (ODC) gene amplification, was grown in the absence of DFMO for a period of 10 months. The gene copy number and methylation status of the ODC gene were monitored after withdrawal of DFMO. Moreover, levels of ODC mRNA, immunoreactive ODC protein, ODC activity and polyamine levels were recorded recurrently during the course of the study. (2) The results revealed that ODC gene copy number started to decrease after 4 weeks growth without DFMO, to a final level of less than 30% of the original gene dosage. The methylation status of the ODC gene, however, remained almost unaltered, displaying only a modest increase in methylation after 10 months without DFMO. The amount of ODC message dropped very rapidly to 75% of the original value, then started to decrease in a gene copy-number-dependent manner. The amount of ODC protein closely followed the levels of mRNA during the study, whereas the ODC activity, after a transient increase during the first week, decreased to half of the original level after 4 weeks. Between 6 and 16 weeks ODC activity stabilized to a fifth of the original value and no more changes were detected during the subsequent period of observation. (3) Due to the grossly elevated ODC enzyme activity, levels of putrescine and spermidine first peaked and then stabilized at 6 weeks after DFMO withdrawal. The final spermidine level was comparable with that of the parental Sultan cell line with only one copy of active ODC gene. However, putrescine content was strikingly elevated, being stabilized to a level that was 20 times higher than in parental cells. Spermine concentration was practically unchanged during the study. (4) According to the results obtained in this study, the abnormal level of ODC expression in human myeloma cells is suppressed partially at the level of transcription or post-transcriptionally, but it is not due to increased methylation of the gene. The major regulatory mechanism to compensate for a highly elevated ODC expression was modulation of the enzyme activity. After 10 months without DFMO, the cells still displayed about 20 times higher ODC activity and putrescine concentration than the myeloma cell line with a single copy of the ODC gene. They did not, however, show any signs of growth retardation or other features different from the parental cells.(ABSTRACT TRUNCATED AT 400 WORDS)
authors.affiliation: A.I. Virtanen Institute, University of Kuopio, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Wahlfors
authors.forename: S
authors.initials: S
authors.lastname: Myöhänen
authors.forename: V P
authors.initials: VP
authors.lastname: Korhonen
authors.forename: L
authors.initials: L
authors.lastname: Alhonen
authors.forename: J
authors.initials: J
authors.lastname: Jänne
mesh_terms: D000818:Animals; D000518:Eflornithine / Q000494:pharmacology; D005784:Gene Amplification; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009101:Multiple Myeloma / Q000201:enzymology* / Q000235:genetics; D009955:Ornithine Decarboxylase / Q000235:genetics* / Q000378:metabolism; D011073:Polyamines / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D011073:Polyamines; D012333:RNA, Messenger; D009955:Ornithine Decarboxylase; D000518:Eflornithine